{
    "abstract": "Background: Non-typeable Haemophilus influenzae (NTHi) is a major cause of various respiratory diseases. The development of an effective vaccine against NTHi mandates new approaches beyond conjugated vaccines as this opportunistic bacterium is non-encapsulated. Here we report on the safety, reactogenicity and immunogenicity of a multi-component investigational vaccine based on three conserved surface proteins from NTHi (proteins D [PD], E [PE] and Pilin A [PilA]) in two observer-blind phase I studies. Methods: In the first study (NCT01657526), 48 healthy 18-40 year-olds received two vaccine formulations (10 or 30 \u03bcg of each antigen [PD and a fusion protein PE-PilA]) or saline placebo at months 0 and 2. In the second study (NCT01678677), 270 50-70 year-olds, current or former smokers, received eight vaccine formulations (10 or 30 \u03bcg antigen/dose non-adjuvanted or adjuvanted with alum, AS01E or AS04C) or saline placebo at months 0, 2 and 6 (plain and alum-adjuvanted groups) and at months 0 and 2 (AS-adjuvanted groups). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post-vaccination, respectively; potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the studies. Humoral and antigen-specific T-cell immunity (in study 2 only) responses were assessed up to 12 months post-vaccination. Results: Observed reactogenicity was highest in the AS-adjuvanted groups but no safety concerns were identified with any of the NTHi vaccine formulations. One fatal SAE (cardiac arrest) not considered related to vaccination, and one pIMD (non-serious psoriasis) in the Placebo group, were reported post-dose 3 in Study 2. All formulations generated a robust antibody response while the AS01-adjuvanted formulations produced the highest humoral and cellular immune responses. Conclusion: This study confirms that the NTHi vaccine formulations had an acceptable reactogenicity and safety profile and were immunogenic in adults. These results justify further clinical development of this NTHi vaccine candidate.",
    "bib_entries": {
        "bib0185": {
            "authors": [
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Van Eldere"
                },
                {
                    "first": "Mary P.E.",
                    "initial": "M.P.E.",
                    "last": "Slack"
                },
                {
                    "first": "Shamez",
                    "initial": "S.",
                    "last": "Ladhani"
                },
                {
                    "first": "Allan W.",
                    "initial": "A.W.",
                    "last": "Cripps"
                }
            ],
            "doi": "10.1016/S1473-3099(14)70734-0",
            "firstpage": "1281",
            "issn": "14733099",
            "lastpage": "1292",
            "pmid": "25012226",
            "pub_year": 2014,
            "title": "Non-typeable Haemophilus influenzae, an under-recognised pathogen",
            "volume": "14"
        },
        "bib0190": {
            "authors": [
                {
                    "first": "Timothy F.",
                    "initial": "T.F.",
                    "last": "Murphy"
                },
                {
                    "first": "Howard",
                    "initial": "H.",
                    "last": "Faden"
                },
                {
                    "first": "Lauren O.",
                    "initial": "L.O.",
                    "last": "Bakaletz"
                },
                {
                    "first": "Jennelle M.",
                    "initial": "J.M.",
                    "last": "Kyd"
                },
                {
                    "first": "Arne",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "Jose",
                    "initial": "J.",
                    "last": "Campos"
                },
                {
                    "first": "Mumtaz",
                    "initial": "M.",
                    "last": "Virji"
                },
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1097/INF.0b013e318184dba2",
            "firstpage": "43",
            "issn": "08913668",
            "lastpage": "48",
            "pmid": "19057458",
            "pub_year": 2009,
            "title": "Nontypeable Haemophilus influenzae as a Pathogen in Children",
            "volume": "28"
        },
        "bib0195": {
            "authors": [
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Dworkin"
                },
                {
                    "first": "Lee",
                    "initial": "L.",
                    "last": "Park"
                },
                {
                    "first": "Stephanie M.",
                    "initial": "S.M.",
                    "last": "Borchardt"
                }
            ],
            "doi": "10.1086/511861",
            "firstpage": "810",
            "issn": "10584838",
            "lastpage": "816",
            "pmid": "17304452",
            "pub_year": 2007,
            "title": "The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons \u226565 years old",
            "volume": "44"
        },
        "bib0200": {
            "authors": [
                {
                    "first": "Shamez",
                    "initial": "S.",
                    "last": "Ladhani"
                },
                {
                    "first": "Mary P.E.",
                    "initial": "M.P.E.",
                    "last": "Slack"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Von Gottberg"
                },
                {
                    "first": "Manosree",
                    "initial": "M.",
                    "last": "Chandra"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "McIntyre"
                },
                {
                    "first": "Lyn",
                    "initial": "L.",
                    "last": "Gilbert"
                },
                {
                    "first": "Geoff",
                    "initial": "G.",
                    "last": "Hogg"
                },
                {
                    "first": "Reinhild",
                    "initial": "R.",
                    "last": "Strauss"
                },
                {
                    "first": "Sigrid",
                    "initial": "S.",
                    "last": "Heuberger"
                },
                {
                    "first": "Germaine",
                    "initial": "G.",
                    "last": "Hanquet"
                },
                {
                    "first": "Francoise",
                    "initial": "F.",
                    "last": "Crokaert"
                },
                {
                    "first": "Pavla",
                    "initial": "P.",
                    "last": "Krizova"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Lebedova"
                },
                {
                    "first": "K\u00e5re",
                    "initial": "K.",
                    "last": "M\u00f8lbak"
                },
                {
                    "first": "Jens J\u00f8rgen",
                    "initial": "J.J.",
                    "last": "Christensen"
                },
                {
                    "first": "Kuulo",
                    "initial": "K.",
                    "last": "Kutsar"
                },
                {
                    "first": "Unna",
                    "initial": "U.",
                    "last": "Joks"
                },
                {
                    "first": "Elja",
                    "initial": "E.",
                    "last": "Herva"
                },
                {
                    "first": "Tarja",
                    "initial": "T.",
                    "last": "Kaijalainen"
                },
                {
                    "first": "Maija",
                    "initial": "M.",
                    "last": "Leinonen"
                },
                {
                    "first": "Petri",
                    "initial": "P.",
                    "last": "Ruutu"
                },
                {
                    "first": "Agnes",
                    "initial": "A.",
                    "last": "Lepoutre"
                },
                {
                    "first": "Henri",
                    "initial": "H.",
                    "last": "Dabernat"
                },
                {
                    "first": "Anette",
                    "initial": "A.",
                    "last": "Siedler"
                },
                {
                    "first": "Heinz J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Theodoridou"
                },
                {
                    "first": "Anastasia",
                    "initial": "A.",
                    "last": "Pangalis"
                },
                {
                    "first": "Georgina",
                    "initial": "G.",
                    "last": "Tzanakaki"
                },
                {
                    "first": "Miklos",
                    "initial": "M.",
                    "last": "Fuzi"
                },
                {
                    "first": "Katalin",
                    "initial": "K.",
                    "last": "Krisztalovics"
                },
                {
                    "first": "Thorolfur",
                    "initial": "T.",
                    "last": "Gudnason"
                },
                {
                    "first": "Hjordis",
                    "initial": "H.",
                    "last": "Hardardottir"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Cafferkey"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Cotter"
                },
                {
                    "first": "Darina",
                    "initial": "D.",
                    "last": "O'Flanagan"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Cerquetti"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Ciofi Degli Atti"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Lucenko"
                },
                {
                    "first": "Grazina",
                    "initial": "G.",
                    "last": "Rimseliene"
                },
                {
                    "first": "Snieguole",
                    "initial": "S.",
                    "last": "Dauksiene"
                },
                {
                    "first": "Pierette",
                    "initial": "P.",
                    "last": "Huberty-Krau"
                },
                {
                    "first": "Francois",
                    "initial": "F.",
                    "last": "Schneider"
                },
                {
                    "first": "Jackie Maistre",
                    "initial": "J.M.",
                    "last": "Melillo"
                },
                {
                    "first": "Sabine",
                    "initial": "S.",
                    "last": "De Greeff"
                },
                {
                    "first": "Hester",
                    "initial": "H.",
                    "last": "De Melker"
                },
                {
                    "first": "Lodewijk",
                    "initial": "L.",
                    "last": "Spanjaard"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Blystad"
                },
                {
                    "first": "E. Arne",
                    "initial": "E.A.",
                    "last": "Hoiby"
                },
                {
                    "first": "\u00d8istein",
                    "initial": "\u00d8.",
                    "last": "L\u00f8voll"
                },
                {
                    "first": "Andrzej",
                    "initial": "A.",
                    "last": "Zielinski"
                },
                {
                    "first": "Waleria",
                    "initial": "W.",
                    "last": "Hryniewicz"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Skoczynska"
                },
                {
                    "first": "Marcin",
                    "initial": "M.",
                    "last": "Kadlubowski"
                },
                {
                    "first": "Laurinda",
                    "initial": "L.",
                    "last": "Queir\u00f3s"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Lavado"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Cameron"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Denham"
                },
                {
                    "first": "Fiona",
                    "initial": "F.",
                    "last": "Johnston"
                },
                {
                    "first": "Margareta",
                    "initial": "M.",
                    "last": "Slacikova"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Novakova"
                },
                {
                    "first": "Alenka",
                    "initial": "A.",
                    "last": "Kraigher"
                },
                {
                    "first": "Metka",
                    "initial": "M.",
                    "last": "Paragi"
                },
                {
                    "first": "Jose",
                    "initial": "J.",
                    "last": "Campos"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Rose Marie",
                    "initial": "R.M.",
                    "last": "Carlsson"
                },
                {
                    "first": "Birgitta Henriques",
                    "initial": "B.H.",
                    "last": "Normark"
                },
                {
                    "first": "Hans Peter",
                    "initial": "H.P.",
                    "last": "Zimmermann"
                }
            ],
            "doi": "10.3201/eid1603.090290",
            "firstpage": "455",
            "issn": "10806040",
            "lastpage": "463",
            "pmid": "20202421",
            "pub_year": 2010,
            "title": "Invasive Haemophilus influenzae disease, Europe, 1996-2006",
            "volume": "16"
        },
        "bib0205": {
            "authors": [
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Hawdon"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Biman"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "McCready"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Brigden"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Malik"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Vergidis"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Kisselgoff"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ulanova"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.113",
            "firstpage": "1235",
            "issn": "0264410X",
            "lastpage": "1238",
            "pmid": "22230580",
            "pub_year": 2012,
            "title": "Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency",
            "volume": "30"
        },
        "bib0210": {
            "authors": [
                {
                    "first": "Lia",
                    "initial": "L.",
                    "last": "Ginaldi"
                },
                {
                    "first": "Maria Francesca",
                    "initial": "M.F.",
                    "last": "Loreto"
                },
                {
                    "first": "Maria Pia",
                    "initial": "M.P.",
                    "last": "Corsi"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Modesti"
                },
                {
                    "first": "Massimo De",
                    "initial": "M.D.",
                    "last": "Martinis"
                }
            ],
            "doi": "10.1016/S1286-4579(01)01443-5",
            "firstpage": "851",
            "issn": "12864579",
            "lastpage": "857",
            "pmid": "11580980",
            "pub_year": 2001,
            "title": "Immunosenescence and infectious diseases",
            "volume": "3"
        },
        "bib0215": {
            "authors": [
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Rita B.",
                    "initial": "R.B.",
                    "last": "Effros"
                }
            ],
            "doi": "10.1016/j.coi.2009.05.023",
            "firstpage": "418",
            "issn": "09527915",
            "lastpage": "424",
            "pmid": "19570667",
            "pub_year": 2009,
            "title": "Immunosenescence: what does it mean to health outcomes in older adults?",
            "volume": "21"
        },
        "bib0220": {
            "authors": [
                {
                    "first": "Mohan",
                    "initial": "M.",
                    "last": "Sopori"
                }
            ],
            "doi": "10.1038/nri803",
            "firstpage": "372",
            "issn": "14741733",
            "lastpage": "377",
            "pmid": "12033743",
            "pub_year": 2002,
            "title": "Effects of cigarette smoke on the immune system",
            "volume": "2"
        },
        "bib0225": {
            "authors": [
                {
                    "first": "Martin R.",
                    "initial": "M.R.",
                    "last": "St\u00e4mpfli"
                },
                {
                    "first": "Gary P.",
                    "initial": "G.P.",
                    "last": "Anderson"
                }
            ],
            "doi": "10.1038/nri2530",
            "firstpage": "377",
            "issn": "14741733",
            "lastpage": "384",
            "pmid": "19330016",
            "pub_year": 2009,
            "title": "How cigarette smoke skews immune responses to promote infection, lung disease and cancer",
            "volume": "9"
        },
        "bib0230": {
            "authors": [
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Lopez"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Shibuya"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Rao"
                },
                {
                    "first": "C. D.",
                    "initial": "C.D.",
                    "last": "Mathers"
                },
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Hansell"
                },
                {
                    "first": "L. S.",
                    "initial": "L.S.",
                    "last": "Held"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Schmid"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Buist"
                }
            ],
            "doi": "10.1183/09031936.06.00025805",
            "firstpage": "397",
            "issn": "09031936",
            "lastpage": "412",
            "pmid": "16452599",
            "pub_year": 2006,
            "title": "Chronic obstructive pulmonary disease: Current burden and future projections",
            "volume": "27"
        },
        "bib0235": {
            "authors": [
                {
                    "first": "A. Sonia",
                    "initial": "A.S.",
                    "last": "Buist"
                },
                {
                    "first": "Mary Ann",
                    "initial": "M.A.",
                    "last": "McBurnie"
                },
                {
                    "first": "William M.",
                    "initial": "W.M.",
                    "last": "Vollmer"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Gillespie"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Burney"
                },
                {
                    "first": "David M.",
                    "initial": "D.M.",
                    "last": "Mannino"
                },
                {
                    "first": "Ana MB",
                    "initial": "A.M.",
                    "last": "Menezes"
                },
                {
                    "first": "Sean D.",
                    "initial": "S.D.",
                    "last": "Sullivan"
                },
                {
                    "first": "Todd A.",
                    "initial": "T.A.",
                    "last": "Lee"
                },
                {
                    "first": "Kevin B.",
                    "initial": "K.B.",
                    "last": "Weiss"
                },
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Jensen"
                },
                {
                    "first": "Guy B.",
                    "initial": "G.B.",
                    "last": "Marks"
                },
                {
                    "first": "Amund",
                    "initial": "A.",
                    "last": "Gulsvik"
                },
                {
                    "first": "Ewa",
                    "initial": "E.",
                    "last": "Nizankowska-Mogilnicka"
                }
            ],
            "doi": "10.1016/S0140-6736(07)61377-4",
            "firstpage": "741",
            "issn": "01406736",
            "lastpage": "750",
            "pmid": "17765523",
            "pub_year": 2007,
            "title": "International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study",
            "volume": "370"
        },
        "bib0240": {
            "authors": [
                {
                    "first": "Klaus F.",
                    "initial": "K.F.",
                    "last": "Rabe"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Hurd"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Anzueto"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Barnes"
                },
                {
                    "first": "Sonia A.",
                    "initial": "S.A.",
                    "last": "Buist"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Calverley"
                },
                {
                    "first": "Yoshinosuke",
                    "initial": "Y.",
                    "last": "Fukuchi"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Jenkins"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Rodriguez-Roisin"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Van Weel"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Zielinski"
                }
            ],
            "doi": "10.1164/rccm.200703-456SO",
            "firstpage": "532",
            "issn": "1073449X",
            "lastpage": "555",
            "pmid": "17507545",
            "pub_year": 2007,
            "title": "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary",
            "volume": "176"
        },
        "bib0245": {
            "authors": [
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Tristram"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Jacobs"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Appelbaum"
                }
            ],
            "doi": "10.1128/CMR.00040-06",
            "firstpage": "368",
            "issn": "08938512",
            "lastpage": "389",
            "pmid": "17428889",
            "pub_year": 2007,
            "title": "Antimicrobial resistance in Haemophilus influenzae",
            "volume": "20"
        },
        "bib0250": {
            "authors": [
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bakaletz"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Cripps"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Denoel"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kyd"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Lobet"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00288-7",
            "firstpage": "S108",
            "issn": "0264410X",
            "lastpage": "S115",
            "pmid": "11163473",
            "pub_year": 2000,
            "title": "Developing a nontypeable Haemophilus influenzae (NTHi) vaccine",
            "volume": "19"
        },
        "bib0255": {
            "authors": [
                {
                    "first": "Timothy F.",
                    "initial": "T.F.",
                    "last": "Murphy"
                }
            ],
            "doi": "10.1128/CVI.00089-15",
            "firstpage": "459",
            "issn": "15566811",
            "lastpage": "466",
            "pmid": "25787137",
            "pub_year": 2015,
            "title": "Vaccines for nontypeable Haemophilus influenzae: The future is now",
            "volume": "22"
        },
        "bib0260": {
            "authors": [
                {
                    "first": "Arne",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                },
                {
                    "first": "H\u00e5kan",
                    "initial": "H.",
                    "last": "Janson"
                }
            ],
            "doi": "10.1086/527396",
            "firstpage": "726",
            "issn": "10584838",
            "lastpage": "731",
            "pmid": "18230042",
            "pub_year": 2008,
            "title": "Protein D of Haemophilus influenzae: A protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines",
            "volume": "46"
        },
        "bib0265": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Peeters"
                },
                {
                    "first": "Viktor",
                    "initial": "V.",
                    "last": "Chrobok"
                },
                {
                    "first": "Pavla",
                    "initial": "P.",
                    "last": "Kriz"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Novakova"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Kaliskova"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Jean Paul",
                    "initial": "J.P.",
                    "last": "Prieels"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1016/S0140-6736(06)68304-9",
            "firstpage": "740",
            "issn": "01406736",
            "lastpage": "748",
            "pmid": "16517274",
            "pub_year": 2006,
            "title": "Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study",
            "volume": "367"
        },
        "bib0270": {
            "authors": [
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Ronander"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Brant"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Eriksson"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "M\u00f6rgelin"
                },
                {
                    "first": "Oskar",
                    "initial": "O.",
                    "last": "Hallgren"
                },
                {
                    "first": "Gunilla",
                    "initial": "G.",
                    "last": "Westergren-Thorsson"
                },
                {
                    "first": "Arne",
                    "initial": "A.",
                    "last": "Forsgren"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.1086/596211",
            "firstpage": "522",
            "issn": "00221899",
            "lastpage": "531",
            "pmid": "19125675",
            "pub_year": 2009,
            "title": "Nontypeable Haemophilus influenzae adhesin protein E: Characterization and biological activity",
            "volume": "199"
        },
        "bib0275": {
            "authors": [
                {
                    "first": "Birendra",
                    "initial": "B.",
                    "last": "Singh"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Brant"
                },
                {
                    "first": "Mogens",
                    "initial": "M.",
                    "last": "Kilian"
                },
                {
                    "first": "Bj\u00f6rn",
                    "initial": "B.",
                    "last": "Hallstr\u00f6m"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.1086/649782",
            "firstpage": "414",
            "issn": "00221899",
            "lastpage": "419",
            "pmid": "20028233",
            "pub_year": 2010,
            "title": "Protein e of haemophilus influenzae is a ubiquitous highly conserved adhesin",
            "volume": "201"
        },
        "bib0280": {
            "authors": [
                {
                    "first": "Diana",
                    "initial": "D.",
                    "last": "Barthel"
                },
                {
                    "first": "Birendra",
                    "initial": "B.",
                    "last": "Singh"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Zipfel"
                }
            ],
            "doi": "10.4049/jimmunol.1101927",
            "firstpage": "379",
            "issn": "00221767",
            "lastpage": "385",
            "pmid": "22124123",
            "pub_year": 2012,
            "title": "Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity",
            "volume": "188"
        },
        "bib0285": {
            "authors": [
                {
                    "first": "Teresia",
                    "initial": "T.",
                    "last": "Hallstr\u00f6m"
                },
                {
                    "first": "Anna M.",
                    "initial": "A.M.",
                    "last": "Blom"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Zipfel"
                },
                {
                    "first": "Kristian",
                    "initial": "K.",
                    "last": "Riesbeck"
                }
            ],
            "doi": "10.4049/jimmunol.0803226",
            "firstpage": "2593",
            "issn": "00221767",
            "lastpage": "2601",
            "pmid": "19635912",
            "pub_year": 2009,
            "title": "Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance",
            "volume": "183"
        },
        "bib0290": {
            "authors": [
                {
                    "first": "Joseph A.",
                    "initial": "J.A.",
                    "last": "Jurcisek"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Bookwalter"
                },
                {
                    "first": "Beth D.",
                    "initial": "B.D.",
                    "last": "Baker"
                },
                {
                    "first": "Soledad",
                    "initial": "S.",
                    "last": "Fernandez"
                },
                {
                    "first": "Laura A.",
                    "initial": "L.A.",
                    "last": "Novotny"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Munson"
                },
                {
                    "first": "Lauren O.",
                    "initial": "L.O.",
                    "last": "Bakaletz"
                }
            ],
            "doi": "10.1111/j.1365-2958.2007.05864.x",
            "firstpage": "1288",
            "issn": "0950382X",
            "lastpage": "1299",
            "pmid": "17645732",
            "pub_year": 2007,
            "title": "The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract",
            "volume": "65"
        },
        "bib0295": {
            "authors": [
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Orr"
                },
                {
                    "first": "Christopher B.",
                    "initial": "C.B.",
                    "last": "Fox"
                }
            ],
            "doi": "10.1038/nm.3409",
            "firstpage": "1597",
            "issn": "10788956",
            "lastpage": "1608",
            "pub_year": 2013,
            "title": "Key roles of adjuvants in modern vaccines",
            "volume": "19"
        },
        "bib0300": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Robbert",
                    "initial": "R.",
                    "last": "Van Der Most"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Geert G.",
                    "initial": "G.G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1007/s10875-010-9490-6",
            "firstpage": "443",
            "issn": "02719142",
            "lastpage": "454",
            "pmid": "21174144",
            "pub_year": 2011,
            "title": "H5N1 influenza vaccine formulated with AS03 A induces strong Cross-reactive and polyfunctional CD4 T-Cell responses",
            "volume": "31"
        },
        "bib0305": {
            "authors": [
                {
                    "first": "Ryan W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                },
                {
                    "first": "Glen",
                    "initial": "G.",
                    "last": "McGillivary"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Lauren O.",
                    "initial": "L.O.",
                    "last": "Bakaletz"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.12.003",
            "firstpage": "1211",
            "issn": "0264410X",
            "lastpage": "1221",
            "pmid": "21167861",
            "pub_year": 2011,
            "title": "Abrogation of nontypeable Haemophilus influenzae Protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media",
            "volume": "29"
        },
        "bib0310": {
            "authors": [
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Berglund"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Vink"
                },
                {
                    "first": "Fernanda Tavares",
                    "initial": "F.T.",
                    "last": "Da Silva"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                }
            ],
            "doi": "10.1128/CVI.00430-13",
            "firstpage": "56",
            "issn": "15566811",
            "lastpage": "65",
            "pmid": "24173029",
            "pub_year": 2014,
            "title": "Safety, immunogenicity, and antibody persistence following an investigational streptococcus pneumoniae and haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults",
            "volume": "21"
        },
        "bib0315": {
            "authors": [
                {
                    "first": "Sunita",
                    "initial": "S.",
                    "last": "Awate"
                },
                {
                    "first": "Lorne A.",
                    "initial": "L.A.",
                    "last": "Babiuk"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Mutwiri"
                }
            ],
            "doi": "10.3389/fimmu.2013.00114",
            "issn": "16643224",
            "pub_year": 2013,
            "title": "Mechanisms of action of adjuvants",
            "volume": "4"
        },
        "bib0320": {
            "authors": [
                {
                    "first": "Arnaud M.",
                    "initial": "A.M.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Collignon"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Sandrine",
                    "initial": "S.",
                    "last": "Wouters"
                },
                {
                    "first": "Kaat",
                    "initial": "K.",
                    "last": "Fierens"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Fochesato"
                },
                {
                    "first": "Najoua",
                    "initial": "N.",
                    "last": "Dendouga"
                },
                {
                    "first": "Christelle",
                    "initial": "C.",
                    "last": "Langlet"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Malissen"
                },
                {
                    "first": "Bart N.",
                    "initial": "B.N.",
                    "last": "Lambrecht"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                }
            ],
            "doi": "10.4049/jimmunol.1400948",
            "firstpage": "1920",
            "issn": "00221767",
            "lastpage": "1930",
            "pmid": "25024381",
            "pub_year": 2014,
            "title": "Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells",
            "volume": "193"
        },
        "bib0325": {
            "authors": [
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Anna C.",
                    "initial": "A.C.",
                    "last": "Nilsson"
                },
                {
                    "first": "Magalie",
                    "initial": "M.",
                    "last": "Caubet"
                },
                {
                    "first": "Thierry G.",
                    "initial": "T.G.",
                    "last": "Pascal"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Pierre G.",
                    "initial": "P.G.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Peter E.",
                    "initial": "P.E.",
                    "last": "Vink"
                }
            ],
            "doi": "10.1128/CVI.00807-13",
            "firstpage": "651",
            "issn": "15566811",
            "lastpage": "660",
            "pmid": "24599529",
            "pub_year": 2014,
            "title": "Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02Vin elderly adults",
            "volume": "21"
        },
        "bib0330": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Horsmans"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.10.052",
            "firstpage": "577",
            "issn": "0264410X",
            "lastpage": "584",
            "pmid": "24176494",
            "pub_year": 2015,
            "title": "Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials",
            "volume": "33"
        },
        "bib0335": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Astrid",
                    "initial": "A.",
                    "last": "Borkowski"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Vanwolleghem"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Eliane",
                    "initial": "E.",
                    "last": "Hons"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                }
            ],
            "doi": "10.1016/S0140-6736(07)61297-5",
            "firstpage": "580",
            "issn": "01406736",
            "lastpage": "589",
            "pmid": "17707753",
            "pub_year": 2007,
            "title": "Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial",
            "volume": "370"
        },
        "bib0340": {
            "authors": [
                {
                    "first": "Christoph R.",
                    "initial": "C.R.",
                    "last": "Arnold"
                },
                {
                    "first": "Juliane",
                    "initial": "J.",
                    "last": "Wolf"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Brunner"
                },
                {
                    "first": "Dietmar",
                    "initial": "D.",
                    "last": "Herndler-Brandstetter"
                },
                {
                    "first": "Beatrix",
                    "initial": "B.",
                    "last": "Grubeck-Loebenstein"
                }
            ],
            "doi": "10.1007/s10875-010-9499-x",
            "firstpage": "137",
            "issn": "02719142",
            "lastpage": "146",
            "pmid": "21243520",
            "pub_year": 2011,
            "title": "Gain and loss of T cell subsets in old age - Age-related reshaping of the T cell repertoire",
            "volume": "31"
        },
        "bib0345": {
            "authors": [
                {
                    "first": "Phyllis Jean",
                    "initial": "P.J.",
                    "last": "Linton"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Dorshkind"
                }
            ],
            "doi": "10.1038/ni1033",
            "firstpage": "133",
            "issn": "15292908",
            "lastpage": "139",
            "pmid": "14749784",
            "pub_year": 2004,
            "title": "Age-related changes in lymphocyte development and function",
            "volume": "5"
        },
        "bib0350": {
            "authors": [
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Chomez"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1586/14760584.6.5.723",
            "firstpage": "723",
            "issn": "14760584",
            "lastpage": "739",
            "pmid": "17931153",
            "pub_year": 2007,
            "title": "GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives",
            "volume": "6"
        },
        "bib0355": {
            "authors": [
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                }
            ],
            "doi": "10.1586/erv.11.29",
            "firstpage": "471",
            "issn": "14760584",
            "lastpage": "486",
            "pmid": "21506645",
            "pub_year": 2011,
            "title": "Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems",
            "volume": "10"
        },
        "bib0360": {
            "authors": [
                {
                    "first": "Kent E.",
                    "initial": "K.E.",
                    "last": "Kester"
                },
                {
                    "first": "James F.",
                    "initial": "J.F.",
                    "last": "Cummings"
                },
                {
                    "first": "Opokua",
                    "initial": "O.",
                    "last": "Ofori-Anyinam"
                },
                {
                    "first": "Christian F.",
                    "initial": "C.F.",
                    "last": "Ockenhouse"
                },
                {
                    "first": "Urszula",
                    "initial": "U.",
                    "last": "Krzych"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Schwenk"
                },
                {
                    "first": "Robin A.",
                    "initial": "R.A.",
                    "last": "Nielsen"
                },
                {
                    "first": "Zufan",
                    "initial": "Z.",
                    "last": "Debebe"
                },
                {
                    "first": "Evgeny",
                    "initial": "E.",
                    "last": "Pinelis"
                },
                {
                    "first": "Laure",
                    "initial": "L.",
                    "last": "Juompan"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Williams"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "Dowler"
                },
                {
                    "first": "V. Ann",
                    "initial": "V.A.",
                    "last": "Stewart"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Wirtz"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Dubois"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lievens"
                },
                {
                    "first": "Joe",
                    "initial": "J.",
                    "last": "Cohen"
                },
                {
                    "first": "W. Ripley",
                    "initial": "W.R.",
                    "last": "Ballou"
                },
                {
                    "first": "D. Gray",
                    "initial": "D.G.",
                    "last": "Heppner"
                }
            ],
            "doi": "10.1086/600120",
            "firstpage": "337",
            "issn": "00221899",
            "lastpage": "346",
            "pmid": "19569965",
            "pub_year": 2009,
            "title": "Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection",
            "volume": "200"
        }
    },
    "body_text": [
        {
            "endOffset": 23000,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Study 1 was a first-time-in-humans, phase I, randomized, observer-blind, placebo-controlled, single-center, dose-escalation study, conducted in Australia, between 08 August 2012 and 25 November 2013.",
            "startOffset": 22801,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 39712,
            "parents": [],
            "secId": "sec0075",
            "sentence": "However, no major differences in the frequency of Grade 3 solicited AEs between adjuvanted and non-adjuvanted vaccine groups and no clear dose-related increases in reactogenicity were observed in Study 2.",
            "startOffset": 39508,
            "title": "Discussion"
        },
        {
            "endOffset": 21519,
            "parents": [],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 21518,
                    "startOffset": 21511
                },
                "bib0255": {
                    "endOffset": 21518,
                    "startOffset": 21511
                }
            },
            "secId": "sec0005",
            "sentence": "Therefore, surface-exposed proteins represent important NTHi vaccine and diagnostic targets [14,15].",
            "startOffset": 21419,
            "title": "Introduction"
        },
        {
            "endOffset": 37748,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "A third dose of plain or alum-adjuvanted vaccine formulation did not change the levels of the observed cellular response (Fig. 4).",
            "startOffset": 37618,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 43272,
            "parents": [],
            "secId": "sec0075",
            "sentence": "In conclusion, the new NTHi vaccine formulations have an acceptable reactogenicity, safety and immunogenicity profile in a limited number of adults per vaccine group.",
            "startOffset": 43106,
            "title": "Discussion"
        },
        {
            "endOffset": 23532,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Study 2 was a phase I, randomized, observer-blind, placebo-controlled, dose-escalation study, conducted in 3 centers in Belgium, between 31 August 2012 and 30 January 2014.",
            "startOffset": 23360,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 36299,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "For PE and PilA, antibody responses after 2 doses of the AS01-adjuvanted formulations were higher compared to the responses after 3 doses of the alum-adjuvanted formulations (lower limits of the 95% CIs of GMC ratios were >2).",
            "startOffset": 36073,
            "title": "Antibody response"
        },
        {
            "endOffset": 38896,
            "parents": [],
            "secId": "sec0075",
            "sentence": "In Study 1, similar levels of reactogenicity (local and systemic) were observed both in placebo and active vaccine recipients.",
            "startOffset": 38770,
            "title": "Discussion"
        },
        {
            "endOffset": 34087,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Nasopharyngitis and headache were the most frequently reported unsolicited AEs.",
            "startOffset": 34008,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34932,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "No clinically relevant laboratory abnormalities were observed during Study 1.",
            "startOffset": 34855,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21124,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 21123,
                    "startOffset": 21119
                }
            },
            "secId": "sec0005",
            "sentence": "Antibiotics should be the first line treatment of NTHi infections, but increasing antibiotic resistance has been observed [13].",
            "startOffset": 20997,
            "title": "Introduction"
        },
        {
            "endOffset": 33575,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, there were 19 grade 3 cases (6 fatigue, 7 gastrointestinal symptoms and 6 headache cases) reported in Placebo (6), AS01 (8), AS04 (3) and in Alum groups (2); 11 out of 19 cases (57.9%) occurred post-Dose 2.",
            "startOffset": 33357,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 29024,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "Seropositivity rates, geometric mean concentrations (GMCs) and geometric mean titers (GMTs) with their 95% CIs were calculated for each study group.",
            "startOffset": 28876,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 25916,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "NTHi PD and PE-PilA fusion protein were prepared using recombinant strains of Escherichia coli, followed by protein purification and sterile filtration.",
            "startOffset": 25764,
            "title": "Study vaccines"
        },
        {
            "endOffset": 30689,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Mean age at first vaccination was 59.4 years; 47.8% were women; 58.9% were current smokers; the majority (98.5%) was of Caucasian origin (Table 2).",
            "startOffset": 30542,
            "title": "Demographics"
        },
        {
            "endOffset": 24639,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The inclusion and exclusion criteria are detailed in Supplementary methods.",
            "startOffset": 24564,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 34384,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "There were 2 cases of grade 3 vaccine-related unsolicited AEs: 1 hypersensitivity case in the 10-AS01 group post-Dose 2 (started 1 day post-vaccination and lasted 4 days) and 1 upper respiratory tract infection in the 30-AS04 group post-Dose 1 (started the day of vaccination and lasted 19 days).",
            "startOffset": 34088,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27461,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Abnormal laboratory findings or other assessments (e.g. abnormal blood pressure) judged by the investigator to be clinically significant were recorded as AE or SAE.",
            "startOffset": 27297,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 38769,
            "parents": [],
            "secId": "sec0075",
            "sentence": "No safety concerns were identified with any of the NTHi vaccine formulations tested.",
            "startOffset": 38685,
            "title": "Discussion"
        },
        {
            "endOffset": 40232,
            "parents": [],
            "secId": "sec0075",
            "sentence": "After 2 doses, immune responses in the AS-adjuvanted groups were higher than in the other groups, with the AS01-adjuvanted formulation inducing the highest response.",
            "startOffset": 40067,
            "title": "Discussion"
        },
        {
            "endOffset": 33914,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "No grade 3 vaccine-related unsolicited AEs were reported.",
            "startOffset": 33857,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28665,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "The incidence of AEs per study group was tabulated with exact 95% confidence intervals (CIs) after each vaccine dose and overall.",
            "startOffset": 28536,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34007,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, 51.7\u201380.0% of the participants reported unsolicited AEs post-Dose 1, 2 and/or 3.",
            "startOffset": 33915,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27778,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "The anti-PD, anti-PE and anti-PilA antibody concentrations were measured by ELISA, using standardized procedures.",
            "startOffset": 27665,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 40066,
            "parents": [],
            "secId": "sec0075",
            "sentence": "Robust and persistent antibody responses post-Dose 1, with a substantial increase post-Dose 2 for the adjuvanted formulations (up to 3.2-fold for PD, 11.6-fold for PE and 10.8-fold for PilA in the 30-AS01 group) and a further increase post-Dose 3 in the alum-adjuvanted groups (up to 2.1-fold for PD, 4.3-fold for PE and 2.0-fold for PilA) were observed.",
            "startOffset": 39712,
            "title": "Discussion"
        },
        {
            "endOffset": 35793,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In Study 1, GMCs for anti-PD, anti-PE and anti-PilA antibodies increased up to Day 90 after each active dose compared to placebo (except for anti-PD in PLAIN groups) (Supplementary Fig. 2).",
            "startOffset": 35604,
            "title": "Antibody response"
        },
        {
            "endOffset": 42046,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 42045,
                    "startOffset": 42042
                }
            },
            "secId": "sec0075",
            "sentence": "Nicotine from the cigarette smoke is the main inhibitor of both the innate and adaptive immune responses [8].",
            "startOffset": 41937,
            "title": "Discussion"
        },
        {
            "endOffset": 28535,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "The safety analysis was performed on the total vaccinated cohort (TVC), which included all vaccinated participants.",
            "startOffset": 28420,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42742,
            "parents": [],
            "refoffsets": {
                "bib0330": {
                    "endOffset": 42741,
                    "startOffset": 42737
                }
            },
            "secId": "sec0075",
            "sentence": "The inclusion of another AS containing MPL and QS-21 (AS02v) in a pneumococcal protein PhtD vaccine was previously shown to partially restore the reduced immune response to vaccines among older adults to the level of vaccine-induced response observed in younger adults [30].",
            "startOffset": 42468,
            "title": "Discussion"
        },
        {
            "endOffset": 20996,
            "parents": [],
            "refoffsets": {
                "bib0230": {
                    "endOffset": 20995,
                    "startOffset": 20988
                },
                "bib0235": {
                    "endOffset": 20995,
                    "startOffset": 20988
                },
                "bib0240": {
                    "endOffset": 20995,
                    "startOffset": 20988
                }
            },
            "secId": "sec0005",
            "sentence": "NTHi infections are responsible for considerable morbidity and healthcare costs while NTHi exacerbations of COPD are also associated with significant mortality rates [10\u201312].",
            "startOffset": 20822,
            "title": "Introduction"
        },
        {
            "endOffset": 41443,
            "parents": [],
            "secId": "sec0075",
            "sentence": "The AS-adjuvanted formulations induced the highest CMI response, with a substantial increase post-Dose 2.",
            "startOffset": 41338,
            "title": "Discussion"
        },
        {
            "endOffset": 20646,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 20645,
                    "startOffset": 20640
                },
                "bib0215": {
                    "endOffset": 20645,
                    "startOffset": 20640
                }
            },
            "secId": "sec0005",
            "sentence": "With older age, comorbidities and immunosenescence are common risk factors for severe infections [6,7].",
            "startOffset": 20543,
            "title": "Introduction"
        },
        {
            "endOffset": 25082,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "These studies have been registered at www.clinicaltrials.gov (NCT01657526 and NCT01678677).",
            "startOffset": 24991,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 37188,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "The specific CD4+ T-cell responses for all NTHi vaccine formulations are presented in Fig. 4.",
            "startOffset": 37095,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 24356,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "These studies were observer-blind, i.e. the vaccine recipients and those responsible for the evaluation of any study endpoint were blinded to the administered vaccines.",
            "startOffset": 24188,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 34488,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "SAEs, unrelated to vaccination, were reported by 2 and 24 participants in Studies 1 and 2, respectively.",
            "startOffset": 34384,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35287,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "No clinically relevant laboratory abnormalities were observed during Study 1.",
            "startOffset": 35210,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26964,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Redness or swelling of diameter >100 mm, temperature >39.5 \u00b0C and other AEs that prevented normal activities were considered as Grade 3.",
            "startOffset": 26828,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31458,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 1, placebo and active vaccine recipients had similar levels of reactogenicity.",
            "startOffset": 31371,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37095,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "In the AS-adjuvanted groups, there was a trend for CD40L, IL-2, TNF-\u03b1 and to a lesser extent IFN-\u03b3, IL-13 and IL-17 expression (Supplementary Fig. 3).",
            "startOffset": 36945,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 29406,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "Seropositivity rates, geometric mean concentrations (GMCs) and geometric mean titers (GMTs) with their 95% CIs were calculated for each study group.",
            "startOffset": 29258,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35210,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "A grade 4 neutropenia (<500 cells/mm3) was reported for 1 participant in the 10-PLAIN group at Day 420 (8 months post-Dose 3).",
            "startOffset": 35084,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33856,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Headache (14/48 [29.2%]) and oropharyngeal pain (8/48 [16.7%]) were the most frequently reported unsolicited AEs both in placebo and vaccine groups.",
            "startOffset": 33708,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37617,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "A waning of the response was seen after the second dose in the AS-adjuvanted groups, but the response at Day 420 remained much higher than the pre-vaccination levels.",
            "startOffset": 37451,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 30804,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 1, placebo and active vaccine recipients had similar levels of reactogenicity.",
            "startOffset": 30717,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37403,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "In the AS-adjuvanted groups, there was a trend for CD40L, IL-2, TNF-\u03b1 and to a lesser extent IFN-\u03b3, IL-13 and IL-17 expression (Supplementary Fig. 3).",
            "startOffset": 37253,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 38972,
            "parents": [],
            "secId": "sec0075",
            "sentence": "In Study 2, there were higher frequencies of reported AEs in the AS groups.",
            "startOffset": 38897,
            "title": "Discussion"
        },
        {
            "endOffset": 28397,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "After PBMC stimulation with the relevant antigens, the frequency of CD4+ and/or CD8+ T-cells expressing a selected set of cytokines (IL-2, IL-13, IL-17, IFN-\u03b3, TNF-\u03b1 and CD40L) or a selected combination of cytokines was evaluated.",
            "startOffset": 28167,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 32025,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "There were 11 cases of grade 3 pain and 3 cases of grade 3 redness, all recorded post-Dose 2 in AS-adjuvanted recipients.",
            "startOffset": 31904,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33356,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 1, 3 grade 3 general AEs cases were reported: 2 fatigue cases (1 post-Dose 1 in Placebo and 1 post-Dose 2 in the 30-PLAIN group) and 1 grade 3 gastrointestinal symptoms post-Dose 1 in Placebo.",
            "startOffset": 33155,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 36560,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Results remained similar when the analysis was done on the TVC.",
            "startOffset": 36497,
            "title": "Antibody response"
        },
        {
            "endOffset": 24564,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Due to differences in the appearance of the study vaccines, vaccines were prepared and administered by authorized medical personnel who did not participate in any of the study clinical evaluations or assays.",
            "startOffset": 24357,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 21880,
            "parents": [],
            "refoffsets": {
                "bib0260": {
                    "endOffset": 21879,
                    "startOffset": 21875
                }
            },
            "secId": "sec0005",
            "sentence": "PD is a highly conserved lipoprotein among encapsulated and non-encapsulated H. influenzae strains [16].",
            "startOffset": 21776,
            "title": "Introduction"
        },
        {
            "endOffset": 38048,
            "parents": [],
            "secId": "sec0075",
            "sentence": "The present studies were primarily designed to assess the safety, reactogenicity and immunogenicity of a new NTHi vaccine candidate based on well conserved surface and virulence factors (PD and PE-PilA) in adults.",
            "startOffset": 37835,
            "title": "Discussion"
        },
        {
            "endOffset": 30247,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "In Study 2, 270 (former) smokers were enrolled and vaccinated, and 257 completed the study (13 withdrawals: 9 consent withdrawals, 3 due to SAEs [1 cardiac arrest, 1 traumatic intracranial hemorrhage and 1 myocardial infarct] and 1 protocol violation [medical history of psoriasis]).",
            "startOffset": 29964,
            "title": "Demographics"
        },
        {
            "endOffset": 20542,
            "parents": [],
            "refoffsets": {
                "bib0195": {
                    "endOffset": 20541,
                    "startOffset": 20536
                },
                "bib0200": {
                    "endOffset": 20541,
                    "startOffset": 20536
                },
                "bib0205": {
                    "endOffset": 20541,
                    "startOffset": 20536
                }
            },
            "secId": "sec0005",
            "sentence": "An increase in NTHi prevalence as an etiological factor of invasive infections has been observed, especially among immunocompromised individuals and the adults [3\u20135].",
            "startOffset": 20376,
            "title": "Introduction"
        },
        {
            "endOffset": 36072,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In Study 2, the AS01-adjuvanted formulations generated the highest observed GMCs (Fig. 3).",
            "startOffset": 35982,
            "title": "Antibody response"
        },
        {
            "endOffset": 24714,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The inclusion and exclusion criteria are detailed in Supplementary methods.",
            "startOffset": 24639,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 36496,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "The GMCs at Day 420 remained much higher compared to pre-vaccination levels in all active groups.",
            "startOffset": 36399,
            "title": "Antibody response"
        },
        {
            "endOffset": 23360,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Healthy 18\u201340 year-olds were enrolled in a staggered manner in 2 steps and randomized using a centralized randomization system on internet (SBIR) (2:1 per step) to receive 2 doses of an NTHi formulation (10 \u03bcg of each antigen [PD and PE-PilA] in step 1 [10-PLAIN group] or 30 \u03bcg of each antigen in step 2 [30-PLAIN group]) or saline placebo at months 0 and 2.",
            "startOffset": 23001,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 25322,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "The primary objective was to evaluate the safety and reactogenicity profile of the NTHi vaccine formulations.",
            "startOffset": 25213,
            "title": "Studies objectives"
        },
        {
            "endOffset": 25641,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "The secondary objectives were to evaluate: the antibody and cell mediated immune (CMI) (Study 2 only) responses to PD, PE and PilA induced by the vaccine formulations prior to, and at 30 days after each vaccination (both studies); and the persistence of the immune responses up to 12 months post-dose 2 (i.e. Day 420).",
            "startOffset": 25323,
            "title": "Studies objectives"
        },
        {
            "endOffset": 40409,
            "parents": [],
            "secId": "sec0075",
            "sentence": "After 3 doses with alum-adjuvanted or plain formulations, the immune responses were lower than those following the administration of 2 doses of the AS01-adjuvanted formulation.",
            "startOffset": 40233,
            "title": "Discussion"
        },
        {
            "endOffset": 26459,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Data were collected in an observer-blind manner (details given in Supplementary).",
            "startOffset": 26378,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28166,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0300": {
                    "endOffset": 28165,
                    "startOffset": 28161
                }
            },
            "secId": "sec0035",
            "sentence": "CMI responses (antigen-specific CD4+ and CD8+ T-cells) were measured only in Study 2, by flow cytometry using intracellular cytokine staining (ICS) on frozen peripheral blood mononuclear cells (PBMCs), following an adaptation of previously described methods [24].",
            "startOffset": 27903,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 41525,
            "parents": [],
            "secId": "sec0075",
            "sentence": "No clear antigen-dose effect could be observed with any of the NTHi formulations.",
            "startOffset": 41444,
            "title": "Discussion"
        },
        {
            "endOffset": 22034,
            "parents": [],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 22033,
                    "startOffset": 22029
                }
            },
            "secId": "sec0005",
            "sentence": "PD is also used as carrier in the licensed pneumococcal polysaccharide PD-conjugate vaccine (PHiD-CV, Synflorix\u2122; GSK Vaccines, Rixensart, Belgium) [17].",
            "startOffset": 21881,
            "title": "Introduction"
        },
        {
            "endOffset": 25763,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Eight formulations were assessed: 10 or 30 \u03bcg antigen (PD and PE-PilA) per dose with or without adjuvant.",
            "startOffset": 25658,
            "title": "Study vaccines"
        },
        {
            "endOffset": 26262,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "NTHi PD and PE-PilA fusion protein were prepared using recombinant strains of Escherichia coli, followed by protein purification and sterile filtration.",
            "startOffset": 26110,
            "title": "Study vaccines"
        },
        {
            "endOffset": 31903,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, pain at the injection site was also the most frequently reported solicited local AE (Fig. 2A), with higher percentages observed in the AS-adjuvanted (point estimates >75%) vs. the plain and alum-adjuvanted groups (point estimates <50%).",
            "startOffset": 31655,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 20375,
            "parents": [],
            "refoffsets": {
                "bib0185": {
                    "endOffset": 20374,
                    "startOffset": 20369
                },
                "bib0190": {
                    "endOffset": 20374,
                    "startOffset": 20369
                }
            },
            "secId": "sec0005",
            "sentence": "Non-typeable Haemophilus influenzae (NTHi) is an opportunistic pathogen and a major cause of various respiratory diseases including otitis media, sinusitis, conjunctivitis, community-acquired pneumonia and exacerbations of chronic obstructive pulmonary disease (COPD) [1,2].",
            "startOffset": 20101,
            "title": "Introduction"
        },
        {
            "endOffset": 30541,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Thirty participants were excluded from the ATP cohort for immunogenicity, mainly due to: essential serological data missing (9 participants), administration of vaccine(s) forbidden by the protocol (7 participants) and non-compliance with the blood sampling schedule (7 participants) (Fig. 1B).",
            "startOffset": 30248,
            "title": "Demographics"
        },
        {
            "endOffset": 25192,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Protocol summaries are available at http://www.gsk-clinicalstudyregister.com (GSK studies 116018 and 116647).",
            "startOffset": 25083,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 39356,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 39355,
                    "startOffset": 39345
                },
                "bib0315": {
                    "endOffset": 39233,
                    "startOffset": 39226
                },
                "bib0320": {
                    "endOffset": 39233,
                    "startOffset": 39226
                },
                "bib0325": {
                    "endOffset": 39355,
                    "startOffset": 39345
                },
                "bib0330": {
                    "endOffset": 39355,
                    "startOffset": 39345
                }
            },
            "secId": "sec0075",
            "sentence": "The higher local and systemic reactogenicity to the AS-adjuvanted formulations may be due to the fact that adjuvants lead to an enhanced migration of monocytes and macrophages to the injection site and an increased production of cytokines and chemokines [27,28]; other adjuvanted formulations have been shown to be more reactogenic than non-adjuvanted vaccine formulations [26,29,30].",
            "startOffset": 38972,
            "title": "Discussion"
        },
        {
            "endOffset": 24815,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.",
            "startOffset": 24714,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 32581,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 1, 3 grade 3 general AEs cases were reported: 2 fatigue cases (1 post-Dose 1 in Placebo and 1 post-Dose 2 in the 30-PLAIN group) and 1 grade 3 gastrointestinal symptoms post-Dose 1 in Placebo.",
            "startOffset": 32380,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 41659,
            "parents": [],
            "secId": "sec0075",
            "sentence": "One of the causes of the low CMI response (especially in the plain formulations) may be the older age of the participants in Study 2.",
            "startOffset": 41526,
            "title": "Discussion"
        },
        {
            "endOffset": 32379,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "During the 7-day post-vaccination period, headache and fatigue were the most frequently reported solicited general AEs in both Study 1 (<62.5% of 30-PLAIN participants post-dose 1) (Supplementary Fig. 1B) and Study 2 with high percentages observed in both 10- and 30-AS01 groups and in the 30-AS04 group (point estimates >20% post-Dose 1 or 2) (Fig. 2B).",
            "startOffset": 32025,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 43513,
            "parents": [],
            "secId": "sec0075",
            "sentence": "These results justify further clinical assessment of the new NTHi vaccine formulations.",
            "startOffset": 43426,
            "title": "Discussion"
        },
        {
            "endOffset": 29697,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "In Study 1, 48 healthy adults were enrolled and vaccinated, and 46 completed the study (1 consent withdrawal and 1 loss to follow-up).",
            "startOffset": 29563,
            "title": "Demographics"
        },
        {
            "endOffset": 34729,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, one fatal SAE was reported in the 30-PLAIN group (cardiac arrest; 50 days post-Dose 3) and 3 other SAE cases did not resolve by Day 420 (1 chronic lymphocytic leukemia, 1 cardiac failure and 1 traumatic intracranial hemorrhage).",
            "startOffset": 34489,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 42137,
            "parents": [],
            "refoffsets": {
                "bib0295": {
                    "endOffset": 42062,
                    "startOffset": 42058
                }
            },
            "secId": "sec0075",
            "sentence": "As expected [23], the induced response to vaccination was improved by the use of adjuvants.",
            "startOffset": 42046,
            "title": "Discussion"
        },
        {
            "endOffset": 40661,
            "parents": [],
            "refoffsets": {
                "bib0335": {
                    "endOffset": 40513,
                    "startOffset": 40509
                }
            },
            "secId": "sec0075",
            "sentence": "Although an AS03-adjuvanted pandemic influenza vaccine has been shown to allow for antigen sparing [31], in our case no clear antigen-dose effect could be observed with the AS01 formulation and the one observed with the other formulations was limited.",
            "startOffset": 40410,
            "title": "Discussion"
        },
        {
            "endOffset": 38165,
            "parents": [],
            "refoffsets": {
                "bib0250": {
                    "endOffset": 38164,
                    "startOffset": 38160
                }
            },
            "secId": "sec0075",
            "sentence": "Animal studies have shown that PD has induced protection against NTHi otitis media in rat and chinchilla models [14].",
            "startOffset": 38048,
            "title": "Discussion"
        },
        {
            "endOffset": 34855,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "One pIMD (non-serious psoriasis) considered related to vaccination was reported at 114 days post-Dose 3 in the Placebo group.",
            "startOffset": 34730,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26787,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Diary cards were used to record solicited local (pain, redness and swelling) and general adverse events (AEs) (fatigue, headache, gastrointestinal symptoms, fever) for 7 days after each vaccine dose and unsolicited AEs for 30 days after each dose.",
            "startOffset": 26540,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28875,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "The immunogenicity analysis was based on the according-to-protocol (ATP) cohort for immunogenicity.",
            "startOffset": 28776,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 26004,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "A detailed description of vaccine presentation and adjuvants is given in Supplementary.",
            "startOffset": 25917,
            "title": "Study vaccines"
        },
        {
            "endOffset": 31371,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "There were 11 cases of grade 3 pain and 3 cases of grade 3 redness, all recorded post-Dose 2 in AS-adjuvanted recipients.",
            "startOffset": 31250,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 41936,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 41935,
                    "startOffset": 41930
                },
                "bib0225": {
                    "endOffset": 41935,
                    "startOffset": 41930
                }
            },
            "secId": "sec0075",
            "sentence": "Alterations of the immune system of adult smokers may be an additional cause of the low immune responses in our case [8,9].",
            "startOffset": 41813,
            "title": "Discussion"
        },
        {
            "endOffset": 33154,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "During the 7-day post-vaccination period, headache and fatigue were the most frequently reported solicited general AEs in both Study 1 (<62.5% of 30-PLAIN participants post-dose 1) (Supplementary Fig. 1B) and Study 2 with high percentages observed in both 10- and 30-AS01 groups and in the 30-AS04 group (point estimates >20% post-Dose 1 or 2) (Fig. 2B).",
            "startOffset": 32800,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37824,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "No detectable specific CD8+ T-cell responses were observed (data not shown).",
            "startOffset": 37748,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 42995,
            "parents": [],
            "secId": "sec0075",
            "sentence": "Functional characterization of the T-cells upon vaccination showed a trend for a dominant CD4+ Th0/Th1 cytokine profile, with CD40L, Il-2 and TNF-\u03b1 expression, and low levels of IFN-\u03b3; very low CD4+ Th2 or Th17 and no CD8+ T-cell induction was observed.",
            "startOffset": 42742,
            "title": "Discussion"
        },
        {
            "endOffset": 26540,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Data were collected in an observer-blind manner (details given in Supplementary).",
            "startOffset": 26459,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31000,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Pain was the most frequently reported solicited local AE during the 7-day post-vaccination period, with only one case of grade 3 pain recorded (Placebo group post-Dose 1) (Supplementary Fig. 1A).",
            "startOffset": 30805,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24990,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "All participants provided written informed consent prior to study entry.",
            "startOffset": 24918,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 35982,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In Study 1, GMCs for anti-PD, anti-PE and anti-PilA antibodies increased up to Day 90 after each active dose compared to placebo (except for anti-PD in PLAIN groups) (Supplementary Fig. 2).",
            "startOffset": 35793,
            "title": "Antibody response"
        },
        {
            "endOffset": 22275,
            "parents": [],
            "refoffsets": {
                "bib0270": {
                    "endOffset": 22138,
                    "startOffset": 22131
                },
                "bib0275": {
                    "endOffset": 22138,
                    "startOffset": 22131
                },
                "bib0280": {
                    "endOffset": 22138,
                    "startOffset": 22131
                },
                "bib0285": {
                    "endOffset": 22138,
                    "startOffset": 22131
                },
                "bib0290": {
                    "endOffset": 22274,
                    "startOffset": 22270
                }
            },
            "secId": "sec0005",
            "sentence": "PE, a highly conserved protein in NTHi, is involved in adhesion and human complement resistance [18\u201321], while PilA plays a role in biofilm formation, adherence to human epithelial cells and colonization of the upper respiratory tract [22].",
            "startOffset": 22035,
            "title": "Introduction"
        },
        {
            "endOffset": 35565,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "A grade 4 neutropenia (<500 cells/mm3) was reported for 1 participant in the 10-PLAIN group at Day 420 (8 months post-Dose 3).",
            "startOffset": 35439,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22755,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Here we report the safety, reactogenicity and immunogenicity results of two phase I trials following administration of 2 or 3 doses of different formulations of NTHi investigational vaccine in adults.",
            "startOffset": 22555,
            "title": "Introduction"
        },
        {
            "endOffset": 24188,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The participants from the AS-adjuvanted groups received saline placebo at month 6.",
            "startOffset": 24106,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 42227,
            "parents": [],
            "secId": "sec0075",
            "sentence": "In our case, the highest CMI response was observed for the AS01E-adjuvanted formulations.",
            "startOffset": 42138,
            "title": "Discussion"
        },
        {
            "endOffset": 29964,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Mean age at first vaccination was 27.0 years; 64.6% were women; the majority (95.8%) was of Caucasian origin (Table 1).",
            "startOffset": 29845,
            "title": "Demographics"
        },
        {
            "endOffset": 35083,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, grade 3 changes in hematological and biochemical levels were reported by a maximum of 2 participants per group (details in Supplementary).",
            "startOffset": 34933,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37252,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "The observed CMI responses in the AS01 groups were the highest.",
            "startOffset": 37189,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 20822,
            "parents": [],
            "refoffsets": {
                "bib0220": {
                    "endOffset": 20821,
                    "startOffset": 20816
                },
                "bib0225": {
                    "endOffset": 20821,
                    "startOffset": 20816
                }
            },
            "secId": "sec0005",
            "sentence": "Another risk factor in adults is smoking, which interferes with mucociliary clearance, diminishes the inflammatory cytokine response and disrupts the epithelial barrier [8,9].",
            "startOffset": 20647,
            "title": "Introduction"
        },
        {
            "endOffset": 38685,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 38684,
                    "startOffset": 38680
                }
            },
            "secId": "sec0075",
            "sentence": "A recent phase I study indicated that a tri-protein investigational vaccine, including PD and 2 pneumococcal proteins, was immunogenic in healthy adults (18\u201340 year-olds) [26].",
            "startOffset": 38509,
            "title": "Discussion"
        },
        {
            "endOffset": 33707,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 1, at least one unsolicited AE was reported by 42/48 (87.5%) of the participants during the 30-day post-vaccination period.",
            "startOffset": 33575,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 41337,
            "parents": [],
            "secId": "sec0075",
            "sentence": "A third dose did not impact the CMI responses for these NTHi formulations.",
            "startOffset": 41263,
            "title": "Discussion"
        },
        {
            "endOffset": 27151,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Data regarding any pregnancy, new medical condition requiring medical attention, potentially immune mediated diseases (pIMDs) and serious AEs (SAEs) were collected throughout the studies.",
            "startOffset": 26964,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24105,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Current and former smokers, 50\u201370 years old, were enrolled in a staggered manner in 2 steps and randomized using SBIR (2:2:2:2:1 per step) to receive 2 or 3 doses of an NTHi vaccine out of 8 different formulations (10 \u03bcg of antigen per dose in step 1 and 30 \u03bcg of each antigen per dose in step 2, either non-adjuvanted [plain] or adjuvanted with alum, AS01E or AS04C [10-PLAIN, 10-AL, 10-AS01, 10-AS04, 30-PLAIN, 30-AL, 30-AS01 and 30-AS04 groups]) or saline placebo at months 0, 2 and 6 for plain and alum-adjuvanted groups and at months 0 and 2 for AS-adjuvanted groups.",
            "startOffset": 23533,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 43425,
            "parents": [],
            "secId": "sec0075",
            "sentence": "All formulations generated a robust antibody response while the AS01-adjuvanted formulations were shown to produce the highest humoral and CMI response.",
            "startOffset": 43273,
            "title": "Discussion"
        },
        {
            "endOffset": 27296,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Hematological and biochemical parameters were measured to assess the subject eligibility at screening, and at Days 7, 60, 67, 180, 187, and 420.",
            "startOffset": 27152,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 32800,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, there were 19 grade 3 cases (6 fatigue, 7 gastrointestinal symptoms and 6 headache cases) reported in Placebo (6), AS01 (8), AS04 (3) and in Alum groups (2); 11 out of 19 cases (57.9%) occurred post-Dose 2.",
            "startOffset": 32582,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 41812,
            "parents": [],
            "refoffsets": {
                "bib0340": {
                    "endOffset": 41811,
                    "startOffset": 41804
                },
                "bib0345": {
                    "endOffset": 41811,
                    "startOffset": 41804
                }
            },
            "secId": "sec0075",
            "sentence": "Age-associated immunosenescence is known to cause a decline in the total number of T-cells and to compromise the T-cell repertoire and function [32,33].",
            "startOffset": 41660,
            "title": "Discussion"
        },
        {
            "endOffset": 29158,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "Details on the statistical analysis of antibody responses, GMC ratios and CMI responses (Study 2) are given in Supplementary methods.",
            "startOffset": 29025,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 21418,
            "parents": [],
            "secId": "sec0005",
            "sentence": "An effective vaccine against NTHi could circumvent this issue, but its development remains a challenge since NTHi is a non-encapsulated bacterium (in contrast to typeable H. influenzae strains) that does not present at the surface polysaccharide chains which could be used as vaccine antigens.",
            "startOffset": 21125,
            "title": "Introduction"
        },
        {
            "endOffset": 27665,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "Blood samples for immunogenicity were taken prior to, and at 30 days after each vaccination, and at 12 months post-dose 2 (i.e. Days 0, 30, 60, 90, 180, 210 and 420).",
            "startOffset": 27499,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 36944,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "The observed CMI responses in the AS01 groups were the highest.",
            "startOffset": 36881,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 31249,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, pain at the injection site was also the most frequently reported solicited local AE (Fig. 2A), with higher percentages observed in the AS-adjuvanted (point estimates >75%) vs. the plain and alum-adjuvanted groups (point estimates <50%).",
            "startOffset": 31001,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 36880,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "The specific CD4+ T-cell responses for all NTHi vaccine formulations are presented in Fig. 4.",
            "startOffset": 36787,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 43106,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 43105,
                    "startOffset": 43101
                }
            },
            "secId": "sec0075",
            "sentence": "For the AS01-adjuvanted formulation, these results are in line with previously shown responses in adults [36].",
            "startOffset": 42996,
            "title": "Discussion"
        },
        {
            "endOffset": 28776,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "All SAEs, withdrawals due to AE(s), pIMDs, pregnancies and all treatment-related AEs were described in detail.",
            "startOffset": 28666,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 41042,
            "parents": [],
            "secId": "sec0075",
            "sentence": "As per design, there was no way to dissociate step effect and dose effect (the participants were enrolled in 2 steps and the lower dose formulation was given in the first step), and therefore it was assumed that there was no step effect.",
            "startOffset": 40805,
            "title": "Discussion"
        },
        {
            "endOffset": 36734,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In Study 2, immunogenicity was also presented per group by smoking status: similar immunogenicity responses were observed for current smokers and ex-smokers (data not shown).",
            "startOffset": 36560,
            "title": "Antibody response"
        },
        {
            "endOffset": 39507,
            "parents": [],
            "secId": "sec0075",
            "sentence": "Our phase I studies enrolled a limited number of subjects, and thus no formal statistical comparisons of reactogenicity between groups were performed.",
            "startOffset": 39357,
            "title": "Discussion"
        },
        {
            "endOffset": 31654,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Pain was the most frequently reported solicited local AE during the 7-day post-vaccination period, with only one case of grade 3 pain recorded (Placebo group post-Dose 1) (Supplementary Fig. 1A).",
            "startOffset": 31459,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24917,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The protocols and associated documents were reviewed and approved by an independent ethics committee.",
            "startOffset": 24816,
            "title": "Studies design and participants"
        },
        {
            "endOffset": 26827,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "AE intensity was graded on a 1\u20133 scale.",
            "startOffset": 26788,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 29257,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "The immunogenicity analysis was based on the according-to-protocol (ATP) cohort for immunogenicity.",
            "startOffset": 29158,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27903,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "The cut-off of the assays was 100 ELISA units (EU)/mL, 8 EU/mL and 7 EU/mL for anti-PD, anti-PE and anti-PilA, respectively.",
            "startOffset": 27779,
            "title": "Humoral and cellular immunogenicity"
        },
        {
            "endOffset": 21775,
            "parents": [],
            "secId": "sec0005",
            "sentence": "We developed a new NTHi multi-component investigational vaccine, based on 3 selected conserved surface proteins in the form of 2 vaccine antigens: a free recombinant protein D (PD) and a recombinant fusion protein combining protein E and Pilin A (PE-PilA).",
            "startOffset": 21519,
            "title": "Introduction"
        },
        {
            "endOffset": 40804,
            "parents": [],
            "secId": "sec0075",
            "sentence": "However, these comparisons were exploratory and have to be interpreted with caution considering that there was no adjustment for multiplicity.",
            "startOffset": 40662,
            "title": "Discussion"
        },
        {
            "endOffset": 42467,
            "parents": [],
            "refoffsets": {
                "bib0350": {
                    "endOffset": 42466,
                    "startOffset": 42459
                },
                "bib0355": {
                    "endOffset": 42466,
                    "startOffset": 42459
                }
            },
            "secId": "sec0075",
            "sentence": "The high humoral and CMI response for the AS01E-adjuvanted formulations was not surprising since the capacity of AS01-based adjuvants to strongly enhance the immune responses was previously demonstrated in various clinical studies [34,35].",
            "startOffset": 42228,
            "title": "Discussion"
        },
        {
            "endOffset": 26109,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Eight formulations were assessed: 10 or 30 \u03bcg antigen (PD and PE-PilA) per dose with or without adjuvant.",
            "startOffset": 26004,
            "title": "Study vaccines"
        },
        {
            "endOffset": 37450,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0070",
            "sentence": "No clear antigen-dose effect could be observed.",
            "startOffset": 37403,
            "title": "Antigen-specific CD4+ and CD8+ T-cells (Study 2)"
        },
        {
            "endOffset": 22555,
            "parents": [],
            "refoffsets": {
                "bib0295": {
                    "endOffset": 22554,
                    "startOffset": 22550
                }
            },
            "secId": "sec0005",
            "sentence": "On top of the classical aluminum hydroxide (alum)-based approach, we have assessed the potential benefit of including an Adjuvant System (AS01 or AS04) in the investigational vaccine, to eventually overcome immunosenescence or impaired immunity in certain target populations [23].",
            "startOffset": 22275,
            "title": "Introduction"
        },
        {
            "endOffset": 38508,
            "parents": [],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 38268,
                    "startOffset": 38264
                },
                "bib0305": {
                    "endOffset": 38507,
                    "startOffset": 38503
                }
            },
            "secId": "sec0075",
            "sentence": "While anti-PD antibodies have been linked to clinical protection against otitis media in children [17], the role of anti-PD antibodies in protection against pulmonary or systemic infections caused by NTHi in adults is yet not known despite the fact that anti-PD antibodies may impair bacterial adherence and phosphorylcholine decoration [25].",
            "startOffset": 38166,
            "title": "Discussion"
        },
        {
            "endOffset": 36398,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                },
                {
                    "id": "sec0060",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In all AS-adjuvanted groups, no clear antigen-dose effect could be observed in antibody responses.",
            "startOffset": 36300,
            "title": "Antibody response"
        },
        {
            "endOffset": 26350,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "A detailed description of vaccine presentation and adjuvants is given in Supplementary.",
            "startOffset": 26263,
            "title": "Study vaccines"
        },
        {
            "endOffset": 29844,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Twenty participants were excluded from the ATP cohort for immunogenicity, mainly because of non-compliance with blood sampling schedule (Fig. 1A).",
            "startOffset": 29698,
            "title": "Demographics"
        },
        {
            "endOffset": 29540,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0040",
            "sentence": "Details on the statistical analysis of antibody responses, GMC ratios and CMI responses (Study 2) are given in Supplementary methods.",
            "startOffset": 29407,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 41262,
            "parents": [],
            "secId": "sec0075",
            "sentence": "The CMI response in terms of CD4+ T-cells expressing at least two markers amongst IL-2, IFN-\u03b3, IL13, IL17, TNF-\u03b1 and CD40L was very low for the plain and for the alum-adjuvanted formulations (especially for PD and PilA).",
            "startOffset": 41042,
            "title": "Discussion"
        },
        {
            "endOffset": 35438,
            "parents": [
                {
                    "id": "sec0045",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "In Study 2, grade 3 changes in hematological and biochemical levels were reported by a maximum of 2 participants per group (details in Supplementary).",
            "startOffset": 35288,
            "title": "Reactogenicity and safety"
        }
    ],
    "docId": "S0264410X16302055",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Geert.LerouxRoels@UGent.be",
                "first": "Geert",
                "initial": "G.",
                "last": "Leroux-Roels"
            },
            {
                "email": "pierre.vandamme@uantwerpen.be",
                "first": "Pierre",
                "initial": "P.",
                "last": "Van Damme"
            },
            {
                "email": "wouter.haazen1@telenet.be",
                "first": "Wouter",
                "initial": "W.",
                "last": "Haazen"
            },
            {
                "email": "sepehr.shakib@sa.gov.au",
                "first": "Sepehr",
                "initial": "S.",
                "last": "Shakib"
            },
            {
                "email": "magalie.caubet@gsk.com",
                "first": "Magalie",
                "initial": "M.",
                "last": "Caubet"
            },
            {
                "email": "emmanuel.x.aris@gsk.com",
                "first": "Emmanuel",
                "initial": "E.",
                "last": "Aris"
            },
            {
                "email": "jeanne-marie.devaster@gsk.com",
                "first": "Jeanne Marie",
                "initial": "J.M.",
                "last": "Devaster"
            },
            {
                "email": "Mathieu.peeters@yahoo.co.uk",
                "first": "Mathieu",
                "initial": "M.",
                "last": "Peeters"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.04.051",
        "firstpage": "3156",
        "issn": "0264410X",
        "keywords": [
            "Adjuvant",
            "Adult vaccination",
            "Immunogenicity",
            "NTHi",
            "Safety"
        ],
        "lastpage": "3163",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults"
    }
}